Navigation Links
Study of Patients on Chronic Opioid Therapy finds Likely Non-adherent Patients Have Increased Healthcare Costs, More Hospital Days
Date:3/17/2011

BALTIMORE, March 17, 2011 /PRNewswire/ -- Patients undergoing opioid therapy for chronic pain who may not be following their prescription regimen have significantly higher overall healthcare costs, Ameritox Ltd. announced recently. The study was published in The American Journal of Managed Care.

"Considering all of the discussion right now around healthcare reform and controlling healthcare spending, this study highlights an opportunity to better manage a costly and at-risk population of patients – those on chronic opioid therapy," said Harry L. Leider, MD, co-author of the study.  Dr. Leider is Chief Medical Officer at Ameritox – a corporate sponsor of the research –and a faculty member with the American College of Physician Executives. "By focusing on patients who receive opioids and are likely non-adherent, clinicians can take concrete steps to improve patient safety and, ultimately, lower costs."  

The study analyzed managed care claims of more than 18 million patients, identifying a subset of pain patients on chronic opioid therapy. The study determined that patients on chronic opioid therapy who were likely non-adherent, as determined by urine drug testing results, had 14 percent higher healthcare costs and 35 percent more hospital days.

Likely non-adherence to prescribed opioid therapy was identified through urine drug monitoring results and included patients with results of a prescribed medication not found, the presence of a non-prescribed drug, the presence of an illicit drug found in the urine, or based on the expected amount of a prescribed drug found.

The study concluded that improving adherence among patients with chronic pain could help reduce healthcare spending and improve health outcomes. "Opioids are an important tool in pain management," added Leider. "This study reinforces a growing belief that pain medication monitoring must be part of the pain management paradigm.  Urine drug monitoring can provide clinicians with information to help improve medication adherence and outcomes among their patients, while controlling overall costs."

Among the Key Findings in the Study:

  • Overall healthcare spending for patients on chronic opioid therapy was over $23,000 per year (2008 dollars)
  • Total healthcare costs were 14 percent higher for likely non-adherent patients ($26,433) over a 12 month period following initial urine drug testing.
  • Likely non-adherent patients had 35 percent more hospital days.

  • About the Study: Data for the study were obtained from a managed care claims database of 18 million people enrolled between July 1, 2005 and Sept. 30, 2008. The data include geographically diverse commercial, Medicare Advantage and Medicaid health plan members in the United States. Data for classification were obtained from an independent database of urine drug testing results. Patients with evidence of long-term prescription opioid use (defined as at least 120 days over any consecutive six month period) were selected for the study. More than 2,100 patients were classified based on urine drug testing results. The study was funded by Ameritox.

    For the full text or a PDF of this study, please go to:

    http://www.ajmc.com/issue/managed-care/2011/2011-1-vol17-n1/AJMC_2011jan_Leider_32to40

    About Ameritox: Ameritox is the nation's leader in pain medication monitoring solutions, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provides physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers Rx Guardian(SM), the most thorough and personalized lab service available and the only pain medication testing program with a proprietary methodology to help physicians assess whether patients are taking their pain medication as directed. Medication monitoring helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, MD with laboratory facilities in Midland, TX and Greensboro, NC.

    To learn more about urine drug monitoring solutions, visit www.ameritox.com.

    © 2011, Ameritox, Ltd. All rights reserved. AMERITOX, the AMERITOX logos, PAIN MEDICATION MONITORING SOLUTIONS, AMERITOX MEDICATION MONITORING SOLUTIONS, Rx GUARDIAN AUTOREMINDER, Rx GUARDIAN and PROTECT YOUR PATIENTS, PROTECT YOUR PRACTICE, are trademarks of Ameritox. All other trademarks are the claimed trademarks of others.For more information, contact: Michele Hart-Henry Ameritox443-769-1610Michele.Hart-Henry@ameritox.com
    '/>"/>

    SOURCE Ameritox Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
    2. Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
    3. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
    4. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
    5. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
    6. BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
    7. Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
    8. DATATRAK Awarded First Study With Kreara Solutions
    9. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
    10. Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
    11. Educational Efforts Reduce COPD Costs by $3.4 Million in East Texas Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
    (Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
    (Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
    Breaking Medicine Technology:
    (Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
    (Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
    (Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
    (Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
    (Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
    Breaking Medicine News(10 mins):